DC homeostasis in hematopoietic stem cell transplantation

References

• Ford CE, Hamerton JL, Barnes DW, Loutit JF. Cytological identification of radiation-chimaeras. Nature 1956; 177: 452–4
   PubMed Web of Science ®Google Scholar
• Baron F, Storb R, Little MT. Hematopoietic cell transplantation: five decades of progress. Arch Med Res 2003; 34: 528–44
   PubMed Web of Science ®Google Scholar
• Hambach L, Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol 2005; 17: 202–10
   Google Scholar
• Burroughs L, Storb R. Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease. Curr Opin Hematol 2005; 12: 45–54
   PubMed Web of Science ®Google Scholar
• Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 10: 1661–72
   Google Scholar
• Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–35
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Brand R, Apperley J, et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002; 100: 3877–86
   PubMed Web of Science ®Google Scholar
• Kanda Y, Izutsu K, Hirai H, et al. Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. Leukemia 2004; 18: 1013–9
   Google Scholar
• Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550–8
   PubMed Web of Science ®Google Scholar
• Bryson JS, Jennings CD, Caywood BE, et al. Enhanced graft-versus-host disease in older recipient mice following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 721–8
   Google Scholar
• Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068–73
   PubMed Web of Science ®Google Scholar
• Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529–33
   PubMed Web of Science ®Google Scholar
• Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98: 3192–204
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767–76
   PubMed Web of Science ®Google Scholar
• den Haan JM, Sherman NE, Blokland E, et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995; 268: 1476–80
   PubMed Web of Science ®Google Scholar
• Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002; 8: 410–4
   PubMed Web of Science ®Google Scholar
• Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 2004; 4: 371
   PubMed Web of Science ®Google Scholar
• Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004; 22: 1136–51
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol 1997; 9: 139–45
   PubMedGoogle Scholar
• Schroeder ML. Transfusion-associated graft-versus-host disease. Br J Haematol 2002; 117: 275–87
   PubMed Web of Science ®Google Scholar
• Johnson BD, Truitt RL. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft–host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 1995; 85: 3302–12
   PubMed Web of Science ®Google Scholar
• Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261–8
   PubMed Web of Science ®Google Scholar
• Shlomchik WD. Antigen presentation in graft-vs.-host disease. Exp Hematol 2003; 31: 1187–97
   PubMed Web of Science ®Google Scholar
• Korngold R, Sprent J. Selection of cytotoxic T-cell precursors specific for minor histocompatibility determinants. I. Negative selection across H-2 barriers induced with disrupted cells but not with glutaraldehyde-treated cells: evidence for antigen processing. J Exp Med 1980; 151: 314–27
   Google Scholar
• Korngold R, Sprent J. Features of T cells causing H-2-restricted lethal graft-vs.-host disease across minor histocompatibility barriers. J Exp Med 1982; 155: 872–83
   PubMed Web of Science ®Google Scholar
• Sprent J, Schaefer M, Lo D, Korngold R. Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences. J Exp Med 1986; 163: 998–1011
   PubMed Web of Science ®Google Scholar
• Gao EK, Kosaka H, Surh CD, Sprent J. T cell contact with Ia antigens on nonhemopoietic cells in vivo can lead to immunity rather than tolerance. J Exp Med 1991; 174: 435–46
   Google Scholar
• Kosaka H, Surh CD, Sprent J. Stimulation of mature unprimed CD8+ T cells by semiprofessional antigen-presenting cells in vivo. J Exp Med 1992; 176: 1291–302
   Google Scholar
• Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412–5
   PubMed Web of Science ®Google Scholar
• Zhang Y, Louboutin JP, Zhu J, et al. Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. J Clin Invest 2002; 109: 1335–44
   PubMed Web of Science ®Google Scholar
• Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8: 575–81
   PubMed Web of Science ®Google Scholar
• Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 2004; 10: 987–92
   PubMed Web of Science ®Google Scholar
• Blaser BW, Schwind NR, Karol S, et al. Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity. Blood 2006; 108: 2463–9
   Google Scholar
• Jones SC, Murphy GF, Friedman TM, Korngold R. Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model. J Clin Invest 2003; 112: 1880–6
   Google Scholar
• Anderson BE, McNiff JM, Jain D, et al. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 2005; 105: 2227–34
   PubMed Web of Science ®Google Scholar
• Mapara MY, Kim YM, Wang SP, et al. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 2002; 100: 1903–9
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Eom HS, Sachs J, et al. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood 2007; 110: 9–17
   PubMed Web of Science ®Google Scholar
• Reddy P, Maeda Y, Liu C, et al. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 2005; 11: 1244–9
   PubMed Web of Science ®Google Scholar
• Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2; 2002: 151–61
   Google Scholar
• Ito T, Liu YJ, Kadowaki N. Functional diversity and plasticity of human dendritic cell subsets. Int J Hematol 2005; 81: 188–96
   PubMed Web of Science ®Google Scholar
• Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90: 3245–87
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245–52
   PubMed Web of Science ®Google Scholar
• Duffner UA, Maeda Y, Cooke KR, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol 2004; 172: 7393–8
   PubMed Web of Science ®Google Scholar
• Xia G, Truitt RL, Johnson BD. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transplant 2006; 12: 397–407
   Google Scholar
• Zhang Y, Shlomchik WD, Joe G, et al. APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease. J Immunol 2002; 169: 7111–8
   PubMed Web of Science ®Google Scholar
• Rowe V, Banovic T, MacDonald KP, et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood 2006; 108: 2485–92
   PubMed Web of Science ®Google Scholar
• Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284: 1835–7
   PubMed Web of Science ®Google Scholar
• Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5: 1219–26
   PubMed Web of Science ®Google Scholar
• Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005; 23: 275–306
   PubMed Web of Science ®Google Scholar
• Brook MO, Wood KJ, Jones ND. The impact of memory T cells on rejection and the induction of tolerance. Transplantation 2006; 82: 1–9
   PubMed Web of Science ®Google Scholar
• Austyn JM, Kupiec-Weglinski JW, Hankins DF, Morris PJ. Migration patterns of dendritic cells in the mouse. Homing to T cell-dependent areas of spleen, and binding within marginal zone. J Exp Med 1988; 167: 646–51
   Google Scholar
• Randolph GJ, Inaba K, Robbiani DF, et al. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 1999; 11: 753–61
   PubMed Web of Science ®Google Scholar
• Kissenpfennig A, Henri S, Dubois B, et al. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 2005; 22: 643–54
   PubMed Web of Science ®Google Scholar
• Pugh CW, MacPherson GG, Steer HW. Characterization of nonlymphoid cells derived from rat peripheral lymph. J Exp Med 1983; 157: 1758–79
   PubMed Web of Science ®Google Scholar
• Hemmi H, Yoshino M, Yamazaki H, et al. Skin antigens in the steady state are trafficked to regional lymph nodes by transforming growth factor-beta1-dependent cells. Int Immunol 2001; 13: 695–704
   PubMed Web of Science ®Google Scholar
• Huang FP, Platt N, Wykes M, et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med 2000; 191: 435–44
   PubMed Web of Science ®Google Scholar
• Scheinecker C, McHugh R, Shevach EM, Germain RN. Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med 2002; 196: 1079–90
   PubMed Web of Science ®Google Scholar
• Belz GT, Behrens GM, Smith CM, et al. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med 2002; 196: 1099–104
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685–711
   PubMed Web of Science ®Google Scholar
• Caux C, Ait-Yahia S, Chemin K, et al. Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol 2000; 22: 345–69
   PubMed Web of Science ®Google Scholar
• Ruedl C, Koebel P, Bachmann M, et al. Anatomical origin of dendritic cells determines their life span in peripheral lymph nodes. J Immunol 2000; 165: 4910–6
   PubMedGoogle Scholar
• Kamath AT, Henri S, Battye F, et al. Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood 2002; 100: 1734–41
   PubMed Web of Science ®Google Scholar
• Kamath AT, Pooley J, O'Keeffe MA, et al. The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J Immunol 2000; 165: 6762–70
   PubMedGoogle Scholar
• Merad M, Manz MG, Karsunky H, et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 2002; 3: 1135–41
   PubMed Web of Science ®Google Scholar
• Merad M, Hoffmann P, Ranheim E, et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 2004; 10: 510–7
   PubMed Web of Science ®Google Scholar
• Katz SI, Tamaki K, Sachs DH. Epidermal Langerhans cells are derived from cells originating in bone marrow. Nature 1979; 282: 324–6
   PubMed Web of Science ®Google Scholar
• Kabashima K, Banks TA, Ansel KM, et al. Intrinsic lymphotoxin-beta receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity 2005; 22: 439–50
   PubMedGoogle Scholar
• Diao J, Winter E, Cantin C, et al. In situ replication of immediate dendritic cell (DC) precursors contributes to conventional DC homeostasis in lymphoid tissue. J Immunol 2006; 176: 7196–206
   PubMedGoogle Scholar
• Bogunovic M, Ginhoux F, Wagers A, et al. Identification of a radio-resistant and cycling dermal dendritic cell population in mice and men. J Exp Med 2006; 203: 2627–38
   Google Scholar
• Liu K, Waskow C, Liu X, et al. Origin of dendritic cells in peripheral lymphoid organs of mice. Nat Immunol 2007; 8: 578–83
   Google Scholar
• Goto Y, Hogg JC, Suwa T, et al. A novel method to quantify the turnover and release of monocytes from the bone marrow using the thymidine analog 5′-bromo-2′-deoxyuridine. Am J Physiol Cell Physiol 2003; 285: C253–9
   PubMed Web of Science ®Google Scholar
• Collin MP, Hart DN, Jackson GH, et al. The fate of human Langerhans cells in hematopoietic stem cell transplantation. J Exp Med 2006; 203: 27–33
   PubMed Web of Science ®Google Scholar
• Kanitakis J, Petruzzo P, Dubernard JM. Turnover of epidermal Langerhans’ cells. N Engl J Med 2004; 351: 2661–2
   Google Scholar
• Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71–82
   PubMed Web of Science ®Google Scholar
• Qu C, Edwards EW, Tacke F, et al. Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes. J Exp Med 2004; 200: 1231–41
   PubMed Web of Science ®Google Scholar
• Ginhoux F, Tacke F, Angeli V, et al. Langerhans cells arise from monocytes in vivo. Nat Immunol 2006; 7: 265–73
   PubMed Web of Science ®Google Scholar
• Naik SH, Metcalf D, van Nieuwenhuijze A, et al. Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. Nat Immunol 2006; 7: 663–71
   PubMed Web of Science ®Google Scholar
• Bruno L, Seidl T, Lanzavecchia A. Mouse pre-immunocytes as non-proliferating multipotent precursors of macrophages, interferon-producing cells, CD8alpha(+) and CD8alpha(−) dendritic cells. Eur J Immunol 2001; 31: 3403–12
   Google Scholar
• Wang Y, Zhang Y, Yoneyama H, et al. Identification of CD8alpha+CD11c− lineage phenotype-negative cells in the spleen as committed precursor of CD8alpha+ dendritic cells. Blood 2002; 100: 569–77
   Google Scholar
• del Hoyo GM, Martin P, Vargas HH , et al. Characterization of a common precursor population for dendritic cells. Nature 2002;415:1043–7; and Erratum 2004;429:205.
   PubMed Web of Science ®Google Scholar
• Diao J, Winter E, Chen W, et al. Characterization of distinct conventional and plasmacytoid dendritic cell-committed precursors in murine bone marrow. J Immunol 2004; 173: 1826–33
   Google Scholar
• Leon B, Martinez del Hoyo G, Parrillas V, et al. Dendritic cell differentiation potential of mouse monocytes: monocytes represent immediate precursors of CD8− and CD8+ splenic dendritic cells. Blood 2004; 103: 2668–76
   Google Scholar
• Yrlid U, Jenkins CD, MacPherson GG. Relationships between distinct blood monocyte subsets and migrating intestinal lymph dendritic cells in vivo under steady-state conditions. J Immunol 2006; 176: 4155–62
   Google Scholar
• Fogg DK, Sibon C, Miled C, et al. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science 2006; 311: 83–7
   PubMed Web of Science ®Google Scholar
• Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 6: 575–81
   Google Scholar
• Kaplan G, Nusrat A, Witmer MD, et al. Distribution and turnover of Langerhans cells during delayed immune responses in human skin. J Exp Med 1987; 165: 763–76
   Google Scholar
• Bennett CL, van Rijn E, Jung S, et al. Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol 2005; 169: 569–76
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Jenison MC, Saeland S, et al. Epidermal Langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity 2005; 23: 611–20
   PubMed Web of Science ®Google Scholar
• Barrett AJ, Mavroudis D, Tisdale J, et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 1998; 21: 543–51
   PubMed Web of Science ®Google Scholar
• Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004; 103: 1548–56
   PubMed Web of Science ®Google Scholar
• Auffermann-Gretzinger S, Lossos IS, Vayntrub TA, et al. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood 2002; 99: 1442–8
   PubMed Web of Science ®Google Scholar
• Chan GW, Gorgun G, Miller KB, Foss FM. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 170–6
   PubMed Web of Science ®Google Scholar
• Clark FJ, Freeman L, Dzionek A, et al. Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease. Transplantation 2003; 75: 221–5
   PubMed Web of Science ®Google Scholar
• Pihusch M, Boeck S, Hamann M, et al. Peripheral dendritic cell chimerism in allogeneic hematopoietic stem cell recipients. Transplantation 2005; 80: 843–9
   Google Scholar
• Boeck S, Hamann M, Pihusch V, et al. Kinetics of dendritic cell chimerism and T cell chimerism in allogeneic hematopoietic stem cell recipients. Bone Marrow Transplant 2006; 37: 57–64
   PubMedGoogle Scholar
• Nachbaur D, Kircher B, Eisendle K, et al. Phenotype, function and chimaerism of monocyte-derived blood dendritic cells after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2003; 123: 119–26
   PubMed Web of Science ®Google Scholar
• Porta MD, Rigolin GM, Alessandrino EP, et al. Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. Eur J Haematol 2004; 72: 18–25
   PubMed Web of Science ®Google Scholar
• Fagnoni FF, Oliviero B, Giorgiani G, et al. Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation. Blood 2004; 104: 281–9
   PubMed Web of Science ®Google Scholar
• Perreault C, Pelletier M, Belanger R, et al. Persistence of host Langerhans cells following allogeneic bone marrow transplantation: possible relationship with acute graft-versus-host disease. Br J Haematol 1985; 60: 253–60
   Google Scholar
• Auffermann-Gretzinger S, Eger L, Bornhauser M, et al. Fast appearance of donor dendritic cells in human skin: dynamics of skin and blood dendritic cells after allogeneic hematopoietic cell transplantation. Transplantation 2006; 81: 866–73
   Google Scholar
• Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004; 104: 2254–62
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–62
   PubMed Web of Science ®Google Scholar
• Hill GR, Cooke KR, Brinson YS, et al. Pretransplant chemotherapy reduces inflammatory cytokine production and acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation 1999; 67: 1478–80
   PubMed Web of Science ®Google Scholar
• Hill GR, Crawford JM, Cooke KR, et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204–13
   PubMed Web of Science ®Google Scholar
• Lee YR, Yang IH, Lee YH, et al. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood 2005; 105: 3951–5
   Google Scholar
• Mehling A, Grabbe S, Voskort M, et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol 2000; 165: 2374–81
   PubMed Web of Science ®Google Scholar
• Piemonti L, Monti P, Allavena P, et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 1999; 162: 6473–81
   PubMed Web of Science ®Google Scholar
• Klangsinsirikul P, Carter GI, Byrne JL, et al. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002; 99: 2586–91
   PubMed Web of Science ®Google Scholar
• Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002; 100: 1715–20
   PubMed Web of Science ®Google Scholar
• Mapara MY, Kim YM, Marx J, Sykes M. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism. Transplantation 2003; 76: 297–305
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Patel M, Harper A, et al. Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc Natl Acad Sci USA 2006; 103: 2758–63
   PubMed Web of Science ®Google Scholar
• Morison WL. Effects of ultraviolet radiation on the immune system in humans. Photochem Photobiol 1989; 50: 515–24
   Google Scholar
• Ullrich SE. The role of epidermal cytokines in the generation of cutaneous immune reactions and ultraviolet radiation-induced immune suppression. Photochem Photobiol 1995; 62: 389–401
   PubMed Web of Science ®Google Scholar
• Barr RM, Walker SL, Tsang W, et al. Suppressed alloantigen presentation, increased TNF-alpha, IL-1, IL-1Ra, IL-10, and modulation of TNF-R in UV-irradiated human skin. J Invest Dermatol 1999; 112: 692–8
   PubMed Web of Science ®Google Scholar
• Meunier L, Bata-Csorgo Z, Cooper KD. In human dermis, ultraviolet radiation induces expansion of a CD36+ CD11b+ CD1− macrophage subset by infiltration and proliferation; CD1+ Langerhans-like dendritic antigen-presenting cells are concomitantly depleted. J Invest Dermatol 1995; 105: 782–8
   PubMedGoogle Scholar
• Yuksel M, Baron E, Camouse M, et al. Peritransplant use of ultraviolet-B irradiation (UV-B) therapy is detrimental to allogeneic stem cell transplantation outcome. Biol Blood Marrow Transplant 2006; 12: 665–71
   Google Scholar
• Hoetzenecker W, Meingassner JG, Ecker R, et al. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004; 122: 673–84
   PubMed Web of Science ®Google Scholar
• Fujii S, Shimizu K, Fujimoto K, et al. Treatment of post-transplanted, relapsed patients with hematological malignancies by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells. Leuk Lymphoma 2001; 42: 357–69
   PubMed Web of Science ®Google Scholar
• Sato K, Yamashita N, Yamashita N, et al. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 2003; 18: 367–79
   PubMed Web of Science ®Google Scholar
• Hock BD, Fearnley DB, Boyce A, et al. Human dendritic cells express a 95 kDa activation/differentiation antigen defined by CMRF-56. Tissue Antigens 1999; 53: 320–34
   Google Scholar
• Hock BD, Starling GC, Daniel PB, Hart DN. Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. Immunology 1994; 83: 573–81
   PubMed Web of Science ®Google Scholar
• Collin MP, Munster D, Clark G, et al. In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: implications for the control of graft-versus-host disease. Transplantation 2005; 79: 722–5
   Google Scholar
• Blazar BR, Korngold R, Vallera DA. Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev 1997; 157: 79–109
   Google Scholar
• Lan YY, De Creus A, Colvin BL, et al. The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am J Transplant 2005; 5: 2649–59
   PubMed Web of Science ®Google Scholar
• Kim YM, Sachs T, Asavaroengchai W, et al. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest 2003; 111: 659–69
   PubMed Web of Science ®Google Scholar
• Maraskovsky E, Pulendran B, Brasel K, et al. Dramatic numerical increase of functionally mature dendritic cells in FLT3 ligand-treated mice. Adv Exp Med Biol 1997; 417: 33–40
   Google Scholar
• Laouar Y, Welte T, Fu XY, Flavell RA. STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity 2003; 19: 903–12
   PubMed Web of Science ®Google Scholar
• McKenna HJ, Stocking KL, Miller RE, et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 2000; 95: 3489–97
   PubMed Web of Science ®Google Scholar
• Whartenby KA, Calabresi PA, McCadden E, et al. Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl Acad Sci USA 2005; 102: 16741–6
   PubMed Web of Science ®Google Scholar
• Saiga K, Toyoda E, Tokunaka K, et al. NK026680, a novel compound suppressive of dendritic cell function, ameliorates mortality in acute lethal graft-versus-host reaction in mice. Bone Marrow Transplant 2006; 37: 317–23
   Google Scholar